Tafasitamab

Research use only, not for human use.

Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.

Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.

Cell Cytotoxicity Assay Cell Line:NHL cell lines and primary CLL and MCL cells by γδ T cells Concentration:Incubation Time:2 h Result:Induced killing of NHL cell lines and primary CLL and MCL cells by γδ T cells.Cell Proliferation Assay Cell Line:SU-DHL-6cells Concentration:Incubation Time:72 h Result:Showed potent antiproliferative effects on tumor cell.Apoptosis Analysis Cell Line:SU-DHL-6cells Concentration:0-4 ng/m L Incubation Time:48 h Result:Showed potent antiproliferative effects due to caspase-induced apoptosis

Animal Model:Disseminated Raji model.Dosage:2.5 μg/kg Administration:Tafasitamab (SC, once on Day 1, 2.5 μg/kg) Result:Showed antitumor activity in disseminated Raji model.Animal Model:Disseminated Ramos model.Dosage:10 mg/kg Administration:Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of10 mg/kg)Result:Showed antitumor activity in disseminated Ramos model.

——

Apoptosis

Apoptosis

Apoptosis | Immunology/Inflammation related

——

——

1422527-84-1

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years